Affiliate disclosure: This article contains affiliate links. If you buy through them, we may earn a commission at no extra cost to you. This does not influence our assessment of the evidence below.
Evidence rating: Moderate — the core nutrients come from one of the largest supplement trials ever run, though the botanical add-ons are thinner
What iGenics Claims To Be
iGenics is a twice-daily eye capsule sold for “clearer, sharper vision,” aimed squarely at people in their fifties and beyond who have noticed blur, glare sensitivity, or eye strain creeping in. Its marketing leans on the phrase “AREDS 2+,” meaning it takes the nutrient combination the National Eye Institute tested in its second Age-Related Eye Disease Study and adds botanicals on top.
That framing is worth pausing on, because it is unusually checkable. Most supplement categories have no landmark trial to point at. Eye nutrition does.
What’s Actually In It
Per two-capsule serving, the label discloses:
The AREDS-style core
- Lutein 20 mg and zeaxanthin 10 mg (from marigold)
- Vitamin C 500 mg, vitamin E, vitamin A 900 mcg
- Zinc 20 mg and copper 2 mg (both as bisglycinate chelates)
The botanical layer
- Bilberry extract 480 mg
- Turmeric extract (95%) 350 mg
- Ginkgo biloba 80 mg
- Saffron 20 mg
- Black pepper extract 20 mg
Doses are listed individually rather than hidden in a proprietary blend, which makes the formula easy to compare against published research — a courtesy a lot of competitors don’t extend.
What The Research Shows
According to PubMed, the evidence splits cleanly into two tiers: nutrients with large randomized trials behind them, and botanicals with small ones.
The AREDS nutrient core is the strongest part of the formula. A Cochrane systematic review covering 26 randomized trials in 11,952 people found that antioxidant vitamin and mineral supplementation of the AREDS type probably slows progression to late age-related macular degeneration — that headline estimate (odds ratio 0.72, 95% CI 0.58–0.90; moderate-certainty evidence) rests on 3 of those studies totalling 2,445 participants. Zinc on its own also showed a lower rate of progression. DOI
But that same review is candid about lutein and zeaxanthin specifically. Compared head-to-head with placebo, lutein/zeaxanthin showed only a small and statistically uncertain effect on progression (risk ratio 0.94, 95% CI 0.87–1.01), rated low-certainty. The carotenoids’ clearest established role was as a replacement for beta-carotene in the original formula — a swap that removed the lung cancer signal seen in former smokers without losing benefit. That is a real advantage, but it is not the same as lutein being a proven vision booster. DOI
A more recent re-analysis found a benefit the original endpoints missed. Pooling 392 eyes from AREDS and 1,210 from AREDS2, investigators measured how fast atrophy crept toward the center of the macula rather than how much total area it covered. On that measure, lutein/zeaxanthin slowed progression toward the central macula significantly (80.1 vs 114.4 µm per year, P = 0.011) — while showing no difference on plain area growth. Same nutrient, different ruler, different answer. DOI
Saffron has small but genuinely randomized support. In a double-blind crossover trial of 100 adults with mild-to-moderate AMD, 20 mg/day of saffron for three months improved best-corrected visual acuity by a mean of 0.69 letters (P = 0.001) and shortened multifocal ERG latency, including among participants already taking AREDS supplements. Adverse events did not differ from placebo. Be honest about the size of that number, though: 0.69 letters is well under one line on an eye chart. DOI
A 2024 trial combined the two and saw visual acuity gains. Thirty patients with neovascular AMD were randomized to anti-VEGF injections alone or anti-VEGF plus a lutein, zeaxanthin, and saffron micronutrient supplement for six months. The supplemented group showed improved visual acuity relative to injections alone, alongside shifts in gut microbiota and fatty acid profiles. The sample is small and the design exploratory, but it is a real randomized trial of this specific nutrient combination. DOI
The Honest Verdict
What holds up: The nutrient backbone here — lutein, zeaxanthin, vitamin C, vitamin E, zinc, copper — is the most heavily trialed combination in all of eye nutrition, and the doses in iGenics sit in the neighborhood of what AREDS2 actually used. Saffron at 20 mg matches the trial dose exactly. That is a formula built by someone who read the papers.
What doesn’t: The benefit demonstrated in those trials is slowing progression of macular degeneration in people who already have it. It is not “improve your vision.” Lutein and zeaxanthin on their own performed unimpressively against placebo in the Cochrane analysis, and saffron’s measured gain was a fraction of a line of acuity. Bilberry, ginkgo, and turmeric are along for the ride on general antioxidant reasoning rather than trial data for this indication.
Who this makes sense for: Someone with diagnosed early or intermediate AMD whose eye doctor has recommended an AREDS-type supplement, and who would rather take one capsule set than three. Cochrane specifically notes that people with intermediate AMD stand to benefit most, since their baseline risk of progression is highest.
Who should skip it: Anyone with healthy eyes expecting a sharpness upgrade — the trials do not support that. Anyone whose blur has not been examined by an optometrist, since refractive error and cataract need a different fix entirely. And anyone already on a separate zinc supplement, since the 20 mg here adds up quickly.
Check current pricing and availability
View iGenics on the official site
This article is for informational purposes only and is not medical advice. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration. Talk to your eye doctor or physician before starting any supplement, especially if you have a diagnosed condition or take medication.
Research cited via PubMed: